Main demographic and clinical characteristics of the two study groups at baseline
| Variable | MS-COVID (n=136) | MS-NCOVID (n=186) | P-value |
| Sex male, number (%) | 55 (40.4%) | 59 (31.7%) | 0.13* |
| Median age (IQR) | 41 (33; 49) | 45 (35; 52) | 0.07† |
| Median disease duration at baseline (IQR) | 9.44 (5.11; 16.44) | 12.35 (3.77; 20.22) | 0.32† |
| Median EDSS at baseline (IQR) | 1.5 (1;3) | 1.5 (1.5;2.5) | 0.50† |
| Phenotype at baseline, number (%) | 0.09* | ||
| RR | 130 (95.6%) | 174 (93.6%) | |
| SP | 2 (1.5%) | 10 (5.9%) | |
| PP | 4 (2.9%) | 2 (1.1%) | |
| Ongoing treatment at baseline, number (%) | 0.50* | ||
| First-line | 76 (55.9%) | 96 (51.6%) | |
| Second-line | 60 (44.1%) | 90 (48.4%) |
*Fisher’s exact test.
†Mann-Whitney U test.
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; PP, primary progressive; RR, relapsing-remitting; SP, secondary progressive.